You are here

Fecal DNA Testing for Colorectal cancer Screening

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 1R43CA183170-01A1
Agency Tracking Number: R43CA183170
Amount: $225,000.00
Phase: Phase I
Program: SBIR
Solicitation Topic Code: NCI
Solicitation Number: PA13-234
Solicitation Year: 2014
Award Year: 2014
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
SOLON, OH 44139-5681
United States
DUNS: 144259343
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 (440) 666-2844
Business Contact
Phone: (440) 666-2844
Research Institution

DESCRIPTION (provided by applicant): This is the Phase I application of a SBIR project that will be devoted to develop a new fecal DNA test for CRC screening, which will utilize a new tri-marker panel discovered in our preliminary study. CRC is the seconddeadliest cancer in USA. The good news is that early detection along with resection is associated with a five-year survival rate of nearly 100%. Fecal DNA testing is emerging as one of the most promising methods to replace fecal occult blood tests for CRCscreening. Recently, we discovered a new panel of stool DNA markers that could detect 86% of CRC with a specificity of 82%. Because this new panel contains no methylated DNA markers, a great benefit of using it for CRC screening is that the quantity of the stool used to extract DNA could be reduced by at least 10 fold, greatly reducing the complexity and cost of fecal DNA testing. To the best of our knowledge, this may be the simplest panel of markers that can achieve such high detection sensitivity w

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government